Tags :Cancer immunotherapy
Targeting MondoA–TXNIP restores antitumour immunity in lactic-acid-induced immunosuppressive microenvironment Summary Cancer cells often produce high levels of lactic acid, creating an immunosuppressive microenvironment. This study investigates targeting the MondoA-TXNIP pathway in this lactic acid-rich Read More
Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer Summary Pancreatic cancer often resists immunotherapy, and this resistance is linked to elevated levels of spermine, a polyamine involved in cell growth and survival. Researchers Read More
The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS Summary AFM28, a bispecific innate cell engager targeting CD123 and CD16A, demonstrates promising results in eliminating leukemic Read More
Targeting the roots of myeloid malignancies with T cell receptors Summary Targeting myeloid malignancies, like leukemia, remains challenging due to disease heterogeneity and relapse risks. A promising approach focuses on using T cell receptors (TCRs) Read More
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/phase 2 trial Summary This Phase 1/Phase 2 trial investigates the safety and efficacy of GD2-targeted CAR T cell therapy in patients with high-risk neuroblastoma, a Read More
GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system Summary GD2 ganglioside, highly expressed in several pediatric central nervous system (CNS) tumors like neuroblastoma and medulloblastoma, presents Read More
Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma Summary Autologous CD19 CAR-T cell therapy shows promise for treating relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). Studies Read More
SARDH in the 1-C metabolism sculpts the T-cell fate and serves as a potential cancer therapeutic target Summary SARAH (Sarcosine Dehydrogenase) plays a crucial role in 1-carbon (1-C) metabolism, a pathway vital for cell growth Read More
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial Summary A phase 2 trial investigated sacituzumab tirumotecan combined with tagitanlimab as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). The study Read More
Nature Immunology, Published online: 18 August 2025; doi:10.1038/s41590-025-02235-2 The authors show that the m6A reader protein YTHDF2 negatively regulates Th9 cell differentiation and function. Ablation of YTHDF2 promotes antigen-specific Th9 cell and Read More
